Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway

Larimar Therapeutics, Inc.

Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.
Open-label study: 43 participants dosed; 82% achieved skin FXN above asymptomatic carriers at 6 months, 100% at 1 year.
mFARS benefit of 2.6 points at 1 year vs natural history; no withdrawals from injection site reactions.
Rolling BLA for accelerated approval started; completion expected 2H 2026; confirmatory Phase 3 first patient dosing expected Q3 2026.
Targeting mid-2027 launch if approved; FDA agreed FXN as surrogate endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.